Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
-- Study Showed Early and Sustained Improvement in Vision Through Six Months --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2009 - Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection)...
VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer-reviewed scientific...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Jul 1, 2009 - Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of...
COPENHAGEN, July 2, 2009--H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).
The primary objective of the study...
BETHESDA, Md.--(BUSINESS WIRE)--Jul 1, 2009 - Sucampo Pharma Americas, Inc., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today reported top-line results from its phase 2 clinical trial of orally administered...
- Results Demonstrate Positive Proof of Mechanism
SAN DIEGO, June 30/PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also...
VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD
HOLLYWOOD, Fla., July 1 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company,...
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE:...
KVISTGAARD, Denmark, July 1/PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most...
Leiden, The Netherlands, July 1, 2009. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that, as part of the activities for the regulatory submission files, it has now...
ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials...
- "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment"
AMSTERDAM, The Netherlands, June 30/PRNewswire/ --New data from an economic analysis presented today at this year's European Society of Human...
Liestal, Switzerland, June 30, 2009 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive data from its Phase IIb study (FJORD). The key finding of the trial is...
Data shows a very high percentage of women responded favorably to a bioidentical and FDA approved hormone therapy for hot flashes
MAPLE GROVE, Minn., June 30 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. presented the results of a secondary...
Prospective Study Seeks to Assess RSV Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research
GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance its commitment to pediatric research...
S. MAMEDE DO CORONADO, Portugal, June 29/PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained...
SOUTHAMPTON, England, June 29/PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of...
SAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in...
Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines Against “Swine” Influenza A (H1N1)
Collaboration of vaccine experts to assess DNA vaccines designed to provide broad...
DuoCort: New chronotherapy for adrenal insufficiency
Helsingborg, Sweden, June 29th 2009 / b3c newswire - DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of...
More...
